Nuvation Bio's Stock Potential Amid Regulatory Progress

Nuvation Bio Inc (NYSE:NUVB) has seen a nearly 170% rise in its shares over the past year, with analysts projecting more than 150% upside potential. The company recently received acceptance from UK regulators for its lung cancer drug taletrectinib and is expanding approvals internationally.

By Abdul Rahman Mon, July 13, 2026 at 12:28 PM GMT+3 2 min read · Yahoo Finance · July 13, 2026, 09:28 UTC

Nuvation Bio's Stock Potential Amid Regulatory Progress

Tickers: $NUVB

Topics: biopharma lung cancer drug regulatory update

Read the full article at Yahoo Finance

More World news

Marvell Technology Appoints Three Independent Directors Prior to Proposed Lumentum Acquisition Seeking Alpha · November 12, 2026, 14:35 UTC
M-tron Industries Reports Q3 2026 GAAP EPS Miss Amid Low Revenue Seeking Alpha · November 12, 2026, 14:37 UTC
Nexxen International Reports Q3 Earnings Beat with Revenue Growth and Increased EBITDA Seeking Alpha · November 12, 2026, 14:30 UTC
Brookfield Corporation Announces Quarterly Dividend of $0.07 Per Share Seeking Alpha · November 12, 2026, 14:30 UTC
Upwork Expands Restructuring Plan to Reduce Workforce by 37% Seeking Alpha · November 12, 2026, 14:34 UTC
Deswell Industries Reports First-Half Revenue of $33.02 Million Amid Segment Shifts Seeking Alpha · November 12, 2026, 14:35 UTC
Avicanna Reports Q3 Results with Positive Adjusted EBITDA and Reduced Operating Losses Seeking Alpha · November 12, 2026, 14:29 UTC
Bridgemarq Real Estate Services Announces Monthly Dividend of CAD 0.0125 per Share Seeking Alpha · November 12, 2026, 14:29 UTC
Natus Medical Expands Global Clinical Collaboration via New EMG and EEG Advisory Boards PR Newswire · November 12, 2026, 14:33 UTC
CoreWeave Reports Strong Third-Quarter Results Driven by AI Demand Motley Fool · November 12, 2026, 14:30 UTC